Early Detection of Prostate Cancer: European Association of Urology Recommendation
(2013) In European Urology 64(3). p.347-354- Abstract
- Background: The recommendations and the updated EAU guidelines consider early detection of PCa with the purpose of reducing PCa-related mortality and the development of advanced or metastatic disease. Objective: This paper presents the recommendations of the European Association of Urology (EAU) for early detection of prostate cancer (PCa) in men without evidence of PCa-related symptoms. Evidence acquisition: The working panel conducted a systematic literature review and meta-analysis of prospective and retrospective clinical studies on baseline prostate-specific antigen (PSA) and early detection of PCa and on PCa screening published between 1990 and 2013 using Cochrane Reviews, Embase, and Medline search strategies. Evidence synthesis:... (More)
- Background: The recommendations and the updated EAU guidelines consider early detection of PCa with the purpose of reducing PCa-related mortality and the development of advanced or metastatic disease. Objective: This paper presents the recommendations of the European Association of Urology (EAU) for early detection of prostate cancer (PCa) in men without evidence of PCa-related symptoms. Evidence acquisition: The working panel conducted a systematic literature review and meta-analysis of prospective and retrospective clinical studies on baseline prostate-specific antigen (PSA) and early detection of PCa and on PCa screening published between 1990 and 2013 using Cochrane Reviews, Embase, and Medline search strategies. Evidence synthesis: The level of evidence and grade of recommendation were analysed according to the principles of evidence-based medicine. The current strategy of the EAU recommends that (1) early detection of PCa reduces PCa-related mortality; (2) early detection of PCa reduces the risk of being diagnosed and developing advanced and metastatic PCa; (3) a baseline serum PSA level should be obtained at 40-45 yr of age; (4) intervals for early detection of PCa should be adapted to the baseline PSA serum concentration; (5) early detection should be offered to men with a life expectancy >= 10 yr; and (6) in the future, multivariable clinical risk-prediction tools need to be integrated into the decision-making process. Conclusions: A baseline serum PSA should be offered to all men 40-45 yr of age to initiate a risk-adapted follow-up approach with the purpose of reducing PCa mortality and the incidence of advanced and metastatic PCa. In the future, the development and application of multivariable risk-prediction tools will be necessary to prevent over diagnosis and over treatment. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4062329
- author
- Heidenreich, Axel ; Abrahamsson, Per-Anders LU ; Artibani, Walter ; Catto, James ; Montorsi, Francesco ; Van Poppel, Hein ; Wirth, Manfred and Mottet, Nicolas
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Prostate Cancer, EAU Guidelines, PSA, Screening, Baseline PSA, Metastasis, Advanced Prostate Cancer
- in
- European Urology
- volume
- 64
- issue
- 3
- pages
- 347 - 354
- publisher
- Elsevier
- external identifiers
-
- wos:000323938700012
- scopus:84881130303
- ISSN
- 1873-7560
- DOI
- 10.1016/j.eururo.2013.06.051
- language
- English
- LU publication?
- yes
- id
- 429fbb34-fee1-4073-91b0-850a0f1a5793 (old id 4062329)
- date added to LUP
- 2016-04-01 15:01:44
- date last changed
- 2022-04-22 06:25:53
@article{429fbb34-fee1-4073-91b0-850a0f1a5793,
abstract = {{Background: The recommendations and the updated EAU guidelines consider early detection of PCa with the purpose of reducing PCa-related mortality and the development of advanced or metastatic disease. Objective: This paper presents the recommendations of the European Association of Urology (EAU) for early detection of prostate cancer (PCa) in men without evidence of PCa-related symptoms. Evidence acquisition: The working panel conducted a systematic literature review and meta-analysis of prospective and retrospective clinical studies on baseline prostate-specific antigen (PSA) and early detection of PCa and on PCa screening published between 1990 and 2013 using Cochrane Reviews, Embase, and Medline search strategies. Evidence synthesis: The level of evidence and grade of recommendation were analysed according to the principles of evidence-based medicine. The current strategy of the EAU recommends that (1) early detection of PCa reduces PCa-related mortality; (2) early detection of PCa reduces the risk of being diagnosed and developing advanced and metastatic PCa; (3) a baseline serum PSA level should be obtained at 40-45 yr of age; (4) intervals for early detection of PCa should be adapted to the baseline PSA serum concentration; (5) early detection should be offered to men with a life expectancy >= 10 yr; and (6) in the future, multivariable clinical risk-prediction tools need to be integrated into the decision-making process. Conclusions: A baseline serum PSA should be offered to all men 40-45 yr of age to initiate a risk-adapted follow-up approach with the purpose of reducing PCa mortality and the incidence of advanced and metastatic PCa. In the future, the development and application of multivariable risk-prediction tools will be necessary to prevent over diagnosis and over treatment. (C) 2013 European Association of Urology. Published by Elsevier B. V. All rights reserved.}},
author = {{Heidenreich, Axel and Abrahamsson, Per-Anders and Artibani, Walter and Catto, James and Montorsi, Francesco and Van Poppel, Hein and Wirth, Manfred and Mottet, Nicolas}},
issn = {{1873-7560}},
keywords = {{Prostate Cancer; EAU Guidelines; PSA; Screening; Baseline PSA; Metastasis; Advanced Prostate Cancer}},
language = {{eng}},
number = {{3}},
pages = {{347--354}},
publisher = {{Elsevier}},
series = {{European Urology}},
title = {{Early Detection of Prostate Cancer: European Association of Urology Recommendation}},
url = {{http://dx.doi.org/10.1016/j.eururo.2013.06.051}},
doi = {{10.1016/j.eururo.2013.06.051}},
volume = {{64}},
year = {{2013}},
}